293 related articles for article (PubMed ID: 16452178)
1. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
2. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
3. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
4. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
Diaconu I; Cerullo V; Escutenaire S; Kanerva A; Bauerschmitz GJ; Hernandez-Alcoceba R; Pesonen S; Hemminki A
J Gene Med; 2010 May; 12(5):435-45. PubMed ID: 20440754
[TBL] [Abstract][Full Text] [Related]
5. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
Wold WS; Toth K
Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
[TBL] [Abstract][Full Text] [Related]
7. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
8. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.
Jogler C; Hoffmann D; Theegarten D; Grunwald T; Uberla K; Wildner O
J Virol; 2006 Apr; 80(7):3549-58. PubMed ID: 16537623
[TBL] [Abstract][Full Text] [Related]
9. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
Wang Y; Xue SA; Hallden G; Francis J; Yuan M; Griffin BE; Lemoine NR
Cancer Res; 2005 Feb; 65(4):1523-31. PubMed ID: 15735041
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
12. Replication-selective oncolytic viruses in the treatment of cancer.
Everts B; van der Poel HG
Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
[TBL] [Abstract][Full Text] [Related]
13. Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.
Tollefson AE; Ying B; Spencer JF; Sagartz JE; Wold WSM; Toth K
J Virol; 2017 May; 91(10):. PubMed ID: 28250128
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
15. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
Dhar D; Spencer JF; Toth K; Wold WS
J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
[TBL] [Abstract][Full Text] [Related]
16. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
17. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
[TBL] [Abstract][Full Text] [Related]
18. Cotton rat tumor model for the evaluation of oncolytic adenoviruses.
Toth K; Spencer JF; Tollefson AE; Kuppuswamy M; Doronin K; Lichtenstein DL; La Regina MC; Prince GA; Wold WS
Hum Gene Ther; 2005 Jan; 16(1):139-46. PubMed ID: 15703497
[TBL] [Abstract][Full Text] [Related]
19. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
20. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]